Ratings STAAR Surgical Company Deutsche Boerse AG

Equities

SR3

US8523123052

Market Closed - Deutsche Boerse AG Other stock markets 07:01:35 30/04/2024 BST			5-day change	1st Jan Change
44.04 ^EUR	+0.82%		+1.43%	+52.44%

04-11	Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating	MT
04-08	Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 2482.78 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
STAAR SURGICAL COMPANY	+52.44%	2.21B	-
ABBOTT LABORATORIES	-3.43%	184B	C+
MEDTRONIC PLC	-1.81%	107B	C
BECTON, DICKINSON AND COMPANY	-4.15%	67.78B	A
DEXCOM, INC.	+1.43%	50.66B	B-
CENCORA, INC.	+11.60%	47.64B	B-
HOYA CORPORATION	+3.06%	41.12B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.03%	26.3B	B
WEST PHARMACEUTICAL SERVICES, INC.	+3.21%	26.04B	A-
TERUMO CORPORATION	+15.17%	25.4B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes